Key result
Colchicine, posterior pericardiotomy, and biomarker-guided strategies reduce postpericardiotomy syndrome incidence after cardiac surgery.
Why the study?
Postpericardiotomy syndrome is common after cardiac surgery, but empirical prevention has historically been used and mechanism-based approaches have not been standardized.
What are the current evidence-based pharmacologic, surgical, and biomarker-based strategies for preventing postpericardiotomy syndrome in cardiac surgery patients?
What are the current evidence-based pharmacologic, surgical, and biomarker-based strategies for preventing postpericardiotomy syndrome in cardiac surgery patients?
Colchicine remains the most evidence-based pharmacologic prophylaxis for postpericardiotomy syndrome, while corticosteroids are not recommended and novel surgical and biomarker strategies offer promising personalized prevention.
Colchicine prophylaxis reduces PPS after cardiac surgery; reinforces RCT evidence for first-line use in eligible patients.
Postpericardiotomy syndrome (PPS) is the most frequent inflammatory after-effect of cardiac surgery and is characterized by high morbidity, delayed hospitalization, and increased long-term mortality rates. Although PPS is common, empirical anti-inflammatory therapy has historically been employed for its prevention, and mechanism-based approaches have not yet been standardized. In this literature review, which was conducted on the basis of randomized controlled trials, meta-analyses, cohort studies, and mechanistic research regarding pharmacologic interventions, surgical modalities, and biomarker-based preventive strategies, the deficiencies of a critical synthesis of existing preventive strategies and emerging risk stratification instruments for PPS are addressed. The review affirms that the most evidence-based pharmacologic intervention is colchicine, which demonstrates a consistent reduction in PPS incidence across a range of randomized trials. Nonsteroidal anti-inflammatory drugs show variable responses, whereas corticosteroids are no longer recommended for routine prophylaxis due to relapse. Specific anti-interleukin-1 therapies represent a promising novel approach for high-risk patients. Surgical interventions, such as pericardial closure using biomaterials and posterior pericardiotomy, are important and do not lead to increased hemodynamic complications, while postoperative effusions, atrial fibrillation, and tamponade are reduced. Less invasive methods may also be employed to mitigate inflammatory causes, particularly in valve-sparing procedures and congenital operations. Emerging biomarker data, including postoperative neutrophil-to-lymphocyte ratios, C-reactive protein levels, and pericardial fluid cytokines, enable the identification of high-risk patients and form the basis for a personalized prevention approach. In summary, pharmacologic prophylaxis, innovative surgical techniques, and biomarker-based risk stratification represent a pathway toward reducing the incidence and burden of PPS in modern cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Ballas et al. (2026) conducted a review in Postpericardiotomy syndrome. Preventive strategies (pharmacologic, surgical, biomarker-based) was evaluated. Colchicine, surgical interventions like posterior pericardiotomy, and biomarker-based risk stratification reduce the incidence and burden of postpericardiotomy syndrome in modern cardiac surgery.
Synapse has enriched 5 related papers. Consider them for comparative context: